Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia
Status:
Unknown status
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Severe acquired aplastic anaemia (SAA) is a life-threatening disease characterized by
pancytopenia and hypoplastic bone marrow. Immunosuppressive treatment with antithymocyte
globulin (ATG)and cyclosporine remain the standard regimen with response rates of 70% or more
and excellent overall survival. However ,there are no clinical trials to illustrate the
response and complete remission rate with different doses of ATG.And there are no data
reported on children with SAA so far.